CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jbm (Healthcare) Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jbm (Healthcare) Ltd
Unit 2303-07, 23/F, Tower 1, Millennium
388 Kwun Tong Road, Kwun Tong, Kowloon
Phone: +852 22672178p:+852 22672178 KOWLOON, Hong Kong Ticker: 21612161
Business Summary
JBM (Healthcare) Ltd is an investment holding company principally engaged in the development, manufacture and distribution of Chinese medicines. The Company operates its business through three segments. The Branded Medicines segment is engaged in the development, manufacture and distribution of branded medicines with chemical compounds as active ingredients. The Proprietary Chinese Medicines segment is engaged in the development, manufacture and distribution of registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal or mineral origin customarily or widely used by the Chinese. The Health and Wellness Products segment is engaged in the distribution and sale of supplements, medical consumables and other nonpharmaceutical products for the general health and wellness of consumers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries
5912 Drug stores and proprietary stores
5999 Miscellaneous retail stores, not elsewhere classified
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Kwong YipSum 59 9/22/2020 9/22/2020
Chief Executive Officer, Executive Director Yat WaiWong 59 1/7/2020 1/7/2020
Vice President - Finance Kau LapLam 36 11/23/2023 7/1/2020
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 279 (As of 9/30/2024)
Outstanding Shares: 814,000,000 (As of 9/30/2024)
Stock Exchange: HKG


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025